Detalhe da pesquisa
1.
Esophageal Cancer Clinical Presentation: Trends in the Last 3 Decades in a Large Italian Series.
Ann Surg
; 267(1): 99-104, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27759616
2.
Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Acta Derm Venereol
; 98(2): 218-224, 2018 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29110018
3.
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.
J Am Acad Dermatol
; 76(2): 264-273.e2, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27847125
4.
Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.
Future Oncol
; 11(9): 1355-62, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25952781
5.
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Lancet Oncol
; 15(4): 436-44, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24582505
6.
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
J Transl Med
; 12: 116, 2014 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24885479
7.
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Cancer Invest
; 32(4): 144-9, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24484235
8.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
J Immunother Cancer
; 12(3)2024 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38485189
9.
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Nat Commun
; 15(1): 146, 2024 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38167503
10.
Antigen rapid diagnostic test monitoring for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients: Is it cost-effective?
Cancer Med
; 12(7): 7795-7800, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36583551
11.
Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel.
J Immunother Cancer
; 10(6)2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35701070
12.
Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study.
Front Oncol
; 11: 627527, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33747946
13.
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).
Eur J Cancer
; 152: 116-128, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34091420
14.
Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome?
Ann Surg
; 252(5): 788-96, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21037434
15.
Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy.
Pharmacogenomics
; 21(6): 393-402, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285752
16.
Cost-effectiveness of a melanoma screening programme using whole disease modelling.
J Med Screen
; 27(3): 157-167, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31711359
17.
An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival.
Front Oncol
; 10: 1652, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33042809
18.
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Eur J Cancer
; 119: 97-106, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31437754
19.
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.
Eur J Cancer
; 107: 175-185, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30580112
20.
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors.
J Immunother Cancer
; 7(1): 308, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730502